Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic Nasopharyngeal Carcinoma: a Prospective, Single-arm Phase 2 Study

NCT06657690 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06657690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06657690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic Nasopharyngeal Carcinoma: a Prospective, Single-arm Phase 2 Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
November 1, 2024
Completion date
October 31, 2027
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic nasopharyngeal carcinoma